Clinical Scorecard: Increased Serum Concentrations of Interleukin-11 and Matrix Metalloproteinase-9 in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
At a Glance
Category
Detail
Condition
Key Mechanisms
Elevated serum levels of Interleukin-11 (IL-11) and Matrix Metalloproteinase-9 (MMP-9); involvement of mast cells (MC) and Epstein-Barr Virus (EBV) in pathogenesis.
Target Population
Care Setting
Key Highlights
ME/CFS is associated with chronic severe fatigue and neurological symptoms.
Significant increase in serum IL-11 and MMP-9 levels in ME/CFS patients compared to healthy controls.
Mast cells stimulated by EBV release MMP-9.
No reliable blood biomarkers currently available for ME/CFS.
ME/CFS affects approximately 3.3 million people in the U.S.
Study utilized ELISA to quantify IL-11 and MMP-9 levels.
Guideline-Based Recommendations
Diagnosis
Management
No effective treatments currently available due to unclear disease mechanisms.
Consider emerging therapies and supportive care options.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Female ME/CFS patients aged 40-60 years.
Current understanding of ME/CFS pathogenesis is insufficient for effective treatment development.
Clinical Best Practices
Conduct thorough patient assessments to meet diagnostic criteria.
Consider the role of viral infections, particularly EBV, in disease pathogenesis.
Stay updated on emerging research regarding biomarkers and treatment options.
Educate patients about ME/CFS and management strategies.
by Baskaran Chinnappan, Duraisamy Kempuraj, Kristina K. Aenlle, Ashley Middleton, Katie S. Day, Sai Puneeth Kothuru, Rhitik Samir Joshi, Nancy G. Klimas, Theoharis C. Theoharides
